Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 206.18

+2.4%

12:52 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Curtis Monnig who wrote (23462)	7/23/1998 9:02:00 PM
From: Peter Singleton	Read Replies (1) of 32384

<< Under the terms of the agreement, Parke-Davis receives exclusive, worldwide development and commercialization rights for up to two RXR subtype selective retinoid preclinical lead compounds identified through the joint efforts of the two companies. In exchange, Allergan will have the opportunity to receive up to $104 million in technology access fees and development milestones, assuming successful development of both lead compounds. Allergan will also be entitled to royalties on net sales of developed products, depending on actual lead compound selection and sales results. Allergan has retained the right to co-promote the second successfully developed compound. >> hmmm .... two pre-clinical RXR compounds, diabetes indication. That's it. $104M cash - not stock - in technology access fees and development milestones. LGND's LLY deal doesn't look so good stacked up against this.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next